Literature DB >> 25371711

Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected cases.

Robert Hoepner1, Simon Faissner1, Gisa Ellrichmann1, Ruth Schneider1, Ralf Gold2.   

Abstract

Entities:  

Year:  2014        PMID： 25371711      PMCID： PMC4218878          DOI： 10.1177/1756285614556287

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN： 1756-2856            Impact factor:   6.570


× No keyword cloud information.
  5 in total

1.  Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Robert Hoepner; Stefanie Dahlhaus; Susanne Kollar; Barbara Zurawski; Andrew Chan; Ingo Kleiter; Ralf Gold; Kerstin Hellwig
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

2.  Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS).

Authors:  Niklas Schmedt; Frank Andersohn; Edeltraut Garbe
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-07-22       Impact factor: 2.890

3.  PML in a patient treated with dimethyl fumarate from a compounding pharmacy.

Authors:  Bob W van Oosten; Joep Killestein; Frederik Barkhof; Chris H Polman; Mike P Wattjes
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

4.  Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?

Authors:  Elisabeth Maillart; Céline Louapre; Catherine Lubetzki; Caroline Papeix
Journal:  Mult Scler       Date:  2013-12-23       Impact factor: 6.312

5.  Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.

Authors:  Stefanie Dahlhaus; Robert Hoepner; Andrew Chan; Ingo Kleiter; Ortwin Adams; Carsten Lukas; Kerstin Hellwig; Ralf Gold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-04-19       Impact factor: 10.154
  5 in total
  3 in total

1.  Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Authors:  Elisabeth Maillart; Jean-Sebastien Vidal; David Brassat; Bruno Stankoff; Agnès Fromont; Jérôme de Sèze; Frédéric Taithe; Pierre Clavelou; Bertrand Bourre; Valérie Delvaux; Audrey Rico; Pierre Labauge; Ayman Tourbah; Christine Lebrun; Jean Pelletier; Thibault Moreau; Céline Louapre; Catherine Lubetzki; Caroline Papeix
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-04-14

2.  Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML).

Authors:  Ruth Schneider; Barbara Bellenberg; Robert Hoepner; Eva-Maria Kolb; Gisa Ellrichmann; Aiden Haghikia; Ralf Gold; Carsten Lukas
Journal:  PLoS One       Date:  2017-04-26       Impact factor: 3.240

3.  Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings.

Authors:  Nidhiben Anadani; Megan Hyland; Roberto Alejandro Cruz; Robert Lisak; Kathleen Costello; Eugene O Major; Yasir Jassam; Ethan Meltzer; Thomas C Varkey; Matthew S Parsons; Andrew D Goodman; Jennifer S Graves; Scott Newsome; Scott S Zamvil; Elliot M Frohman; Teresa C Frohman
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-12-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.